Active	Status	Sponsor type	Region	Phase	Filter
7 Active 2 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ANGELUCCI, Emanuele
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL	Active, not recruiting	3	240	Europe, Canada, US, RoW	Brentuximab vedotin, Rituximab, Lenalidomide, Placebo	Seagen Inc.	Diffuse Large B-cell Lymphoma	05/25	04/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	Active, not recruiting	2	82	Europe, US, RoW	brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone	Seagen Inc.	Peripheral T-cell Lymphoma	05/24	12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients	Active, not recruiting	2	168	Europe, RoW	MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab	Miltenyi Biomedicine GmbH, ICON plc	Diffuse Large B-cell Lymphoma	12/24	07/29
NCT03620318: Individual Patient Compassionate Use of Crenolanib	Available	N/A		Europe	Crenolanib besylate	Arog Pharmaceuticals, Inc.	FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V, PDGFRA Gene Amplification